Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This phase I study has been designed to establish the safety, tolerability and maximum
tolerated dose (MTD) of four separate regimens for patients with metastatic breast cancer:
dose- escalating BKM120 when combined with capecitabine (Arm A), with capecitabine and
trastuzumab (Arm C), or with capecitabine and lapatinib (Arm D) and dose- escalating BEZ235
when combined with capecitabine (Arm B).